Treatments for dysarthria in Parkinson's disease (Q35868680)

10 August 2017

1 reference

title

Treatments for dysarthria in Parkinson's disease (English)

1 reference

10 August 2017

1 reference

1 reference

Serge Pinto

1

1 reference

10 August 2017

Canan Ozsancak

2

1 reference

10 August 2017

Elina Tripoliti

3

1 reference

10 August 2017

Stéphane Thobois

4

1 reference

10 August 2017

Patricia Limousin-Dowsey

5

1 reference

10 August 2017

Pascal Auzou

6

1 reference

10 August 2017

1 September 2004

1 reference

10 August 2017

1 reference

10 August 2017

3

1 reference

10 August 2017

9

1 reference

10 August 2017

547-556

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900854-3

10 August 2017

1 reference

7 January 2021

Speech and swallowing symptoms associated with Parkinson's disease and multiple sclerosis: a survey

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900854-3

7 January 2021

Differential Diagnostic Patterns of Dysarthria

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900854-3

7 January 2021

Individual manifestations of Parkinson's disease after ten or more years of levodopa

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900854-3

7 January 2021

Parkinson's disease: disability, review, and management

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900854-3

7 January 2021

Clusters of Deviant Speech Dimensions in the Dysarthrias

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900854-3

7 January 2021

SPEECH CHARACTERISTICS OF PATIENTS WITH PARKINSON'S DISEASE: I. INTENSITY, PITCH, AND DURATION

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900854-3

7 January 2021

SPEECH CHARACTERISTICS OF PATIENTS WITH PARKINSON'S DISEASE. 3. ARTICULATION, DIADOCHOKINESIS, AND OVER-ALL SPEECH ADEQUACY.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900854-3

7 January 2021

Effects of speech therapy and pharmacologic and surgical treatments on voice and speech in Parkinson's disease: a review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900854-3

7 January 2021

The effects of speech therapy and pharmacological treatments on voice and speech in Parkinson s disease: a review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900854-3

7 January 2021

The functional anatomy of basal ganglia disorders

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900854-3

7 January 2021

Functional architecture of basal ganglia circuits: neural substrates of parallel processing

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900854-3

7 January 2021

Primate models of movement disorders of basal ganglia origin

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900854-3

7 January 2021

Clinical observations on the rate of progression of idiopathic parkinsonism

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900854-3

7 January 2021

Does long-term aggravation of Parkinson's disease result from nondopaminergic lesions?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900854-3

7 January 2021

Brain regions involved in articulation.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900854-3

7 January 2021

Does the cerebellum contribute to cognitive aspects of speech production? A functional magnetic resonance imaging (fMRI) study in humans.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900854-3

7 January 2021

Motor mechanisms in speech ontogeny: phylogenetic, neurobiological and linguistic implications

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900854-3

7 January 2021

A new brain region for coordinating speech articulation

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900854-3

7 January 2021

A functional magnetic resonance imaging study of the role of left posterior superior temporal gyrus in speech production: implications for the explanation of conduction aphasia.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900854-3

7 January 2021

Hypophonia in Parkinson's disease: neural correlates of voice treatment revealed by PET.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900854-3

7 January 2021

Subthalamic nucleus stimulation and dysarthria in Parkinson's disease: a PET study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900854-3

7 January 2021

Aromatic Amino Acids and Modification of Parkinsonism

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900854-3

7 January 2021

Treatment of Parkinsonism With Levodopa

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900854-3

7 January 2021

Parkinson's disease: medical treatment of moderate to advanced disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900854-3

7 January 2021

"On-off" effects in patients with Parkinson's disease on chronic levodopa therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900854-3

7 January 2021

Speech changes in parkinsonism during L-dopa therapy: preliminary findings

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900854-3

7 January 2021

Periodicity of speech in Parkinsonism.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900854-3

7 January 2021

Variations in axial, proximal, and distal motor response to L-dopa in multisystem atrophy and Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900854-3

7 January 2021

Effect of thalamotomy and levodopa therapy on the speech of Parkinson patients

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900854-3

7 January 2021

Letter: Peak-dose dysphonia in parkinsonism

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900854-3

7 January 2021

Developmental stuttering and Parkinson's disease: the effects of levodopa treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900854-3

7 January 2021

Repetitive speech phenomena in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900854-3

7 January 2021

Speech changes in Parkinson's disease during treatment with L-dopa

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900854-3

7 January 2021

Parkinsonian speech disfluencies: effects of l-dopa-related fluctuations

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900854-3

7 January 2021

Aerodynamic measurements of patients with Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900854-3

7 January 2021

The effect of levodopa on vocal function in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900854-3

7 January 2021

Effects of levodopa on laryngeal muscle activity for voice onset and offset in Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900854-3

7 January 2021

Phonatory characteristics of parkinsonian speech before and after morning medication: the ON and OFF states.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900854-3

7 January 2021

Handwriting and speech changes across the levodopa cycle in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900854-3

7 January 2021

Breathing pattern in patients with Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900854-3

7 January 2021

Effect of L-dopa on speech in Parkinsonism : An EMG study of labial articulatory function

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900854-3

7 January 2021

Lip Muscle Function in Parkinsonian Dysarthria

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900854-3

7 January 2021

Speech defects of parkinsonian patients: Effects of levodopa therapy on speech intelligibility

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900854-3

7 January 2021

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900854-3

1 reference

7 January 2021

Speech motor control in Parkinson's disease: a comparison between a clinical assessment protocol and a quantitative analysis of mandibular movements

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900854-3

7 January 2021

Piribedil (ET 495) in the treatment of Parkinson's disease combined with amantadine or levodopa

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900854-3

7 January 2021

Pergolide therapy in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900854-3

7 January 2021

Bromocriptine combined with levodopa in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900854-3

7 January 2021

Changes in vocal intensity in Parkinson's disease following pallidotomy surgery

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900854-3

7 January 2021

Electromyographic Studies of Facial Muscle Activity in Speech

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900854-3

7 January 2021

Effects of central dopaminergic stimulation by apomorphine on speech in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900854-3

7 January 2021

Speech dysfunction in early Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900854-3

7 January 2021

A CRITICAL ANALYSIS OF THE EFFECTS OF TRIHEXYPHENIDYL (ARTANE) ON THE COMPONENTS OF THE PARKINSONIAN SYNDROME

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900854-3

7 January 2021

Speech disorders of Parkinsonism: a review

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900854-3

7 January 2021

A double-blind trial of clonazepam in the treatment of parkinsonian dysarthria

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900854-3

7 January 2021

Amantadine-induced "vocal" myoclonus

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900854-3

7 January 2021

Sequence heterogeneity in Parkinsonian speech.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900854-3

7 January 2021

Parkinsonian deficits in serial multiarticulate movements for speech

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900854-3

7 January 2021

Intensive voice treatment (LSVT) for patients with Parkinson's disease: a 2 year follow up.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900854-3

7 January 2021

Speech therapy and Parkinson's disease: a review and further data

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900854-3

7 January 2021

Effect of voice rehabilitation on oral communication of Parkinson's disease patients

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900854-3

7 January 2021

Speech disorder in Parkinsonism; use of delayed auditory feedback in selected cases

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900854-3

7 January 2021

A microcomputer-based wearable biofeedback device to improve transfer of treatment in parkinsonian dysarthria

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900854-3

7 January 2021

Regulation of parkinsonian speech volume: the effect of interlocuter distance

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900854-3

7 January 2021

Changes in vocal loudness following intensive voice treatment (LSVT) in individuals with Parkinson's disease: a comparison with untreated patients and normal age-matched controls.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900854-3

7 January 2021

Speech motor stability in IPD: effects of rate and loudness manipulations

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900854-3

7 January 2021

Intensive speech treatment for patients with Parkinson's disease: short-and long-term comparison of two techniques

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900854-3

7 January 2021

Comparison of two forms of intensive speech treatment for Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900854-3

7 January 2021

Phonatory and articulatory changes associated with increased vocal intensity in Parkinson disease: a case study.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900854-3

7 January 2021

Intensive voice treatment in Parkinson disease: laryngostroboscopic findings

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900854-3

7 January 2021

Speech therapy for Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900854-3

7 January 2021

Swallowing and voice effects of Lee Silverman Voice Treatment (LSVT): a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900854-3

7 January 2021

Speech functions of the thalamus inferred from the effects of thalamotomy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900854-3

7 January 2021

Speech disturbances following stereotaxic surgery in ventrolateral thalamus.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900854-3

7 January 2021

Disturbances of the temporal organization of speech following bilateral thalamic surgery in a patient with Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900854-3

7 January 2021

Development of palilalia after stereotaxic thalamotomy in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900854-3

7 January 2021

Unilateral pallidotomy versus bilateral subthalamic nucleus stimulation in PD: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900854-3

7 January 2021

Ventroposterolateral pallidotomy can abolish all parkinsonian symptoms

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900854-3

7 January 2021

Speech problems in parkinsonian patients undergoing anterior choroidal artery occlusion or chemopallidectomy.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900854-3

7 January 2021

Bilateral contemporaneous posteroventral pallidotomy for the treatment of Parkinson's disease: neuropsychological and neurological side effects. Report of four cases and review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900854-3

7 January 2021

The results, indications, and physiology of posteroventral pallidotomy for patients with Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900854-3

7 January 2021

Outcomes after stereotactically guided pallidotomy for advanced Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900854-3

7 January 2021

Posteroventral medial pallidotomy in advanced Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900854-3

7 January 2021

Unilateral and bilateral pallidotomy for idiopathic Parkinson's disease: a case series of 115 patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900854-3

7 January 2021

Neuropsychological, neurological and functional outcome following pallidotomy for Parkinson's disease. A consecutive series of eight simultaneous bilateral and twelve unilateral procedures.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900854-3

7 January 2021

Declines in switching underlie verbal fluency changes after unilateral pallidal surgery in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900854-3

7 January 2021

Voice and speech characteristics of persons with Parkinson's disease pre- and post-pallidotomy surgery: preliminary findings.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900854-3

7 January 2021

Dorsal subthalamotomy for Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900854-3

7 January 2021

Bilateral dorsolateral subthalamotomy for advanced Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900854-3

7 January 2021

Stereotactic subthalamic nucleus lesioning for the treatment of Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900854-3

7 January 2021

Postural asymmetries following unilateral subthalomotomy for advanced Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900854-3

7 January 2021

Treatment of advanced Parkinson's disease by subthalamotomy: one-year results.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900854-3

7 January 2021

Lesioning the subthalamic nucleus in the treatment of Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900854-3

7 January 2021

High-frequency stimulation of the globus pallidus internalis in Parkinson's disease: a study of seven cases

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900854-3

7 January 2021

Electrical stimulation of the subthalamic nucleus in advanced Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900854-3

7 January 2021

Effects of subthalamic nucleus stimulation on parkinsonian dysarthria and speech intelligibility

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900854-3

7 January 2021

Deep brain stimulation is preferable to thalamotomy for tremor suppression.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900854-3

7 January 2021

Thalamic deep brain stimulation for the treatment of head, voice, and bilateral limb tremor

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900854-3

7 January 2021

Thalamic deep brain stimulation for tremor-predominant Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900854-3

7 January 2021

Efficiency and safety of bilateral contemporaneous pallidal stimulation (deep brain stimulation) in levodopa-responsive patients with Parkinson's disease with severe motor fluctuations: a 2-year follow-up review

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900854-3

7 January 2021

Deep brain stimulation for the treatment of Parkinson's disease: subthalamic nucleus versus globus pallidus internus

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900854-3

7 January 2021

Long-term efficacy of globus pallidus stimulation for the treatment of Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900854-3

7 January 2021

Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900854-3

7 January 2021

'Speech initiation hesitation' following subthalamic nucleus stimulation in a patient with Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900854-3

7 January 2021

Bilateral subthalamic nucleus stimulation in a parkinsonian patient with preoperative deficits in speech and cognition: persistent improvement in mobility but increased dependency: a case study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900854-3

7 January 2021

Bilateral subthalamic stimulation effects on oral force control in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900854-3

7 January 2021

Effect of stimulation of the subthalamic nucleus on oral control of patients with parkinsonism

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900854-3

7 January 2021

Effect of bilateral stimulation of the subthalamic nucleus on parkinsonian voice

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900854-3

7 January 2021

Effect of bilateral stimulation of the subthalamic nucleus on parkinsonian dysarthria

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900854-3

7 January 2021

Effect of bilateral deep-brain stimulation on oral control of patients with parkinsonism

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900854-3

7 January 2021

Lateralized effects of subthalamic nucleus stimulation on different aspects of speech in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900854-3

7 January 2021

The effect of unilateral electrostimulation of the subthalamic nucleus on respiratory/phonatory subsystems of speech production in Parkinson's disease--a preliminary report.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900854-3

7 January 2021

Bilateral chronic electrostimulation of ventroposterolateral pallidum: a new therapeutic approach for alleviating all parkinsonian symptoms.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900854-3

7 January 2021

Effect of parkinsonian signs and symptoms of bilateral subthalamic nucleus stimulation

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900854-3

7 January 2021

Parkinson's disease, subthalamic stimulation, and selection of candidates: a pathological study.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900854-3

7 January 2021

Preliminary voice and speech analysis following fetal dopamine transplants in 5 individuals with Parkinson disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900854-3

7 January 2021

Treatment of Parkinson hypophonia with percutaneous collagen augmentation

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900854-3

7 January 2021

Percutaneous laryngeal collagen augmentation for treatment of parkinsonian hypophonia

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900854-3

7 January 2021

Treatment of hypophonia with collagen vocal cord augmentation in patients with parkinsonism

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900854-3

7 January 2021

Speech impairment in Parkinson's disease is improved by transcranial application of electromagnetic fields

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900854-3

7 January 2021

Effects of a music therapy voice protocol on speech intelligibility, vocal acoustic measures, and mood of individuals with Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2804%2900854-3

7 January 2021

10.1016/S1474-4422(04)00854-3

Identifiers

DOI

1 reference

10 August 2017

1 reference